Once-daily LIXIANA® – an oral, direct factor Xa inhibitor indicated for1:

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

Simple and convenient once-daily dosing

Once-daily dosing, with or without food – consistent across both nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE*) indications.1

Efficacy and safety data

Demonstrated in two large Phase 3 clinical trials in nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE).6,7


Clinical trial designs

Robust clinical trials designed to reflect the nonvalvular atrial fibrillation (NVAF), deep vein thrombosis (DVT) and pulmonary embolism (PE) patients you may see in your daily clinical practice.6,7

Practical guide

Practical guidance to support you when prescribing LIXIANA®.


Healthcare professional resources

Download useful resources to use in your practice and view journal articles.


Contact us

If you are based in the UK and have any questions about LIXIANA®, Daiichi Sankyo or this website, please get in touch.

Indications

Introducing once-daily LIXIANA® (edoxaban) – an oral, direct factor Xa inhibitor indicated for:1
  • • Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)
  • • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT or PE in adults Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT or PE in adults

Now NICE recommended and SMC accepted in NVAF and VTE2-5

Now NICE recommended and SMC accepted in NVAF and VTE2-5
Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with NVAF, and for treating and preventing recurrent DVT and PE in adults.2,3

Dosing Information

Dosing information
Once-daily dosing, with or without food – consistent across both NVAF and VTE* indications. 1

Practical guide

Practical guide
Practical guidance to support you when prescribing LIXIANA®

Healthcare professional resources

Healthcare professional resources
Download useful resources to use in your practice and view journal articles

Efficacy and Safety

Efficacy and Safety
Proven efficacy comparable to
well-controlled warfarin in nonvalvular atrial fibrillation (NVAF), with a superior reduction in major bleeding6
Proven efficacy comparable to
well-controlled warfarin in venous thromboembolism (VTE), with a superior reduction in clinically relevant bleeding7

Clinical Trials

ENGAGE AF-TIMI 48: Largest and longest comparative NVAF trial to date with a NOAC (non-Vitamin K antagonist oral anticoagulant).6
Hokusai-VTE is the largest single comparative VTE trial to date with a NOAC (non-Vitamin K antagonist oral anticoagulant).7
Hokusai-VTE

Contact us

Contact us
If you are based in the UK and have any questions about LIXIANA®, Daiichi Sankyo or this website, please get in touch.
  • *

    Following initial use of heparin for at least 5 days 

  • **

    The primary safety endpoint of ENGAGE AF-TIMI 48 was the incidence of adjudicated major bleeding, defined by the International Society on Thrombosis and Haemostasis (ISTH) as (i) fatal bleeding; and/or (ii) symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome, and/or (iii) bleeding causing a fall in haemoglobin level of 2.0 g/dL or more, or leading to transfusion of two or more units of whole blood or red cells.8

  • The primary safety endpoint of Hokusai-VTE was a composite of major and clinically relevant nonmajor bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH). Major bleeding was defined as overt bleeding associated with a decrease in haemoglobin of 2.0 g/L or more, or requiring a transfusion of 2 or more units of blood, occurring in a critical site or contributing to death.8 Clinically relevant non major bleeding was defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with other discomfort such as pain, or impairment of activities daily life.9